New Drugs in Hematology

Bologna, Royal Hotel Carlton

Monday, October 1, 2018

Three recent “impressive” stories

Chairman: P. Corradini

Checkpoint inhibitors

A. Younes

Daratumumab

M. Cavo

SESSION I: Classical Ph1-neg myeloproliferative neoplasms

Chairmen: F. Passamonti, A.M. Vannucchi

Status of the art of treatment

C. Harrison

Ruxolitinib in myelo brosis

F. Passamonti

Ruxolitinib in polycitemia vera

A.M. Vannucchi

New drugs and combination therapy

J.O. Mascarenhas

Allotransplant in myelo brosis

A. Bacigalupo

SESSION II: Hodgkin’s lymphoma

Chairmen: A. Younes, P.L. Zinzani

Status of the art of treatment

A. Younes

Nivolumab

A. Younes

Pembrolizumab

R. Chen

Brentuximab vedotin

A.J. Moskowitz

New Combo-steps

S.M. Ansell

Focus on: Prognostic factor and prediction of response in lymphoma

Chairman: B.D. Cheson

Can we use imaging to predict response?

C.H. Moskowitz<

Role of circulating tumor DNA in response prediction and assessment of clonal evolution

D. Rossi

SESSION III: Acute leukemia

Chairmen: M. Levis, G. Martinelli

Status of the art: from genomic knowledge to target therapy in leukemias

L. Bullinger

Gliteritinib

M. Levis

Quizartinib

J.E. Cortes

SY-1425

J.G. Jurcic

Inotuzumab in ALL

E. Jabbour

Venetoclax

M.Y. Konopleva

Idasanutlin

C. Papayannidis

Ponatinib

E. Jabbour

Tuesday, October 2, 2018

SESSION IV: Non-Hodgkin’s lymphoma (I)

Chairmen: S.M. Ansell, C. Deng

Status of the art of treatment

S.M. Ansell

MOR208

W.J. Jurczak

Mogamulizumab

M. Ogura

Betalutin

A. Kolstad

Pixantrone

R. Pettengel

SESSION V: Chronic lymphocitic leukemia

Chairmen: A. Cuneo, R. Foà

Status of the art of management

S.M. O’Brien

Idelalisib

A.D. Zelenetz

Zanubrutinib (BGB-3111)

C. Tam

Umbralisib (TGR-1202)

A.R. Mato

Focus on: “The old, the new and the future in the same drug”

Chairman: M. Spina

Bendamustine

B.D. Cheson

Umbralisib (TGR-1202)

A.R. Mato

SESSION VI: Non-Hodgkin’s lymphoma (II)

Chairmen: N.H. Fowler, U. Vitolo

Zanubrutinib (BGB-3111)

C. Tam

Venetoclax

S.A. Rule

Idelalisib

S.M. Ansell

Duvelisib

I.W. Flinn

ME-401

A. Zelenetz

Acalabrutinib

S.A. Rule

Selinexor

J. Kuruvilla

Wednesday, October 3, 2018

Lectures

Chairman: P.L. Zinzani

Thrombotic thrombocytopenic purpura: a look at the future

A. Artoni

G100 + Pembrolizumab

C. Paya

SESSION VII: Multiple myeloma

Chairmen: M. Cavo, P.G. Richardson

New proteasome inhibitors (Oprozomib, Marizomib)

P.G. Richardson

Selinexor

N. Bahlis

Venetoclax

P. Moreau

Monoclonal antibodies: Isatuximab, MOR202

S.K. Kumar

Monoclonal antibodies and BTKs: anti-PD-1/PDL-1, Ibrutinib

R. Vij

SESSION VIII: Chronic myeloid leukemia

Chairman: G. Rosti

Bosutinib

G. Rosti

CAR-T and other immunotherapies

I.M. Borrello

Imatinib, nilotinib and dasatinib frontline: which and why?

J.L. Steegmann

ABI001 and combination

M. Breccia

Ponatinib

M. Baccarani

Treatment free remission

G. Rosti